MUC2 and mucinous neoplasm: Treatment with celecoxib effectively reduced mucinous tumor growth inhibition in vivo, supporting our hypothesis that mucinous tumors may be especially vulnerable to a therapeutic strategy that simultaneously suppresses MUC2 suppression and induces apoptosis.